LAG3 and metastatic melanoma: A subsequent study found that metastatic melanoma patients who responded to anti-LAG-3 and anti-PD-1 combination therapy had higher baseline TCR clonality with CD8+LAG-3+ clones that expanded and shifted to a more cytotoxic phenotype resembling NK cells (Huuhtanen et al., 2023).